Literature DB >> 15752559

Molecular mechanisms that set the stage for DC-T cell engagement.

Klaas P J M van Gisbergen1, Lutz C Paessens, Teunis B H Geijtenbeek, Yvette van Kooyk.   

Abstract

The unsurpassed capacity of dendritic cells (DC) to prime naive T cells is thought to depend on the formation of an immunological synapse. DC-SIGN, a C-type lectin exclusively expressed at the cell surface of DC, functions as an adhesion receptor facilitating T cell binding and priming through recognition of glycosylated ICAM-3 on naive T cells. Yet, DC-SIGN also mediates binding to pathogens such as HIV by recognizing glycosylated gp120. The scope of the present study was to investigate whether DC-SIGN upon recognition of its cellular ligand and pathogenic ligand affects DC synapse formation and activation/mobilization of other adhesion receptors such as LFA-1 to the cell contact site. Using a DC-SIGN deletion mutant, we show that DC-SIGN is a constitutively active receptor that mediates ligand binding independent of signaling through the cytoplasmic domain. Surprisingly, initial binding of gp120 to DC-SIGN did not result in increased adhesion levels of LFA-1 to its ligand ICAM-1 in both immature DC and Raji-DC-SIGN cells. However, ligand binding to DC-SIGN induced recruitment of LFA-1 to the adhesion site. Moreover, we could demonstrate that activation of LFA-1 results in DC-SIGN-LFA-1 co-clustering in the cell membrane. This triggers binding of ligands to LFA-1 that are shared with DC-SIGN, such as ICAM-3, but not of ligands that are not shared with DC-SIGN, such as ICAM-1. Thus, we propose that upon ligand binding DC-SIGN recruits LFA-1 to the contact site, resulting in the formation of DC-SIGN-LFA-1 co-clusters, in which the initial DC-SIGN-mediated interactions with ligand are transient and eventually shift to more stable LFA-1-dependent interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15752559     DOI: 10.1016/j.imlet.2004.11.008

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation.

Authors:  Nicholas A Zumwalde; Eisuke Domae; Matthew F Mescher; Yoji Shimizu
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

2.  Organization of the integrin LFA-1 in nanoclusters regulates its activity.

Authors:  Alessandra Cambi; Ben Joosten; Marjolein Koopman; Frank de Lange; Inge Beeren; Ruurd Torensma; Jack A Fransen; Maria Garcia-Parajó; Frank N van Leeuwen; Carl G Figdor
Journal:  Mol Biol Cell       Date:  2006-07-19       Impact factor: 4.138

3.  Impaired dendritic cell function in aging leads to defective antitumor immunity.

Authors:  Annabelle Grolleau-Julius; Erin K Harning; Lisa M Abernathy; Raymond L Yung
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 4.  Cellular and viral mechanisms of HIV-1 transmission mediated by dendritic cells.

Authors:  Christopher M Coleman; Corine St Gelais; Li Wu
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17.

Authors:  Curtis J Henry; David A Ornelles; Latoya M Mitchell; Kristina L Brzoza-Lewis; Elizabeth M Hiltbold
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

6.  Probiotic Gut Microbiota Isolate Interacts with Dendritic Cells via Glycosylated Heterotrimeric Pili.

Authors:  Hanne L P Tytgat; Nienke H van Teijlingen; Ruby May A Sullan; François P Douillard; Pia Rasinkangas; Marcel Messing; Justus Reunanen; Reetta Satokari; Jos Vanderleyden; Yves F Dufrêne; Teunis B H Geijtenbeek; Willem M de Vos; Sarah Lebeer
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 7.  Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity.

Authors:  Jaxaira Maggi; Carolina Schafer; Gabriela Ubilla-Olguín; Diego Catalán; Katina Schinnerling; Juan C Aguillón
Journal:  Front Immunol       Date:  2015-09-22       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.